Found: 6
Select item for more details and to access through your institution.
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 201, n. 1, p. 43, doi. 10.1007/s10549-023-06998-w
- By:
- Publication type:
- Article
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 200, n. 3, p. 43, doi. 10.1007/s10549-023-06998-w
- By:
- Publication type:
- Article
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cover Picture: A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy (ChemMedChem 3/2014).
- Published in:
- ChemMedChem, 2014, v. 9, n. 3, p. 413, doi. 10.1002/cmdc.201490005
- By:
- Publication type:
- Article
A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer Therapy.
- Published in:
- ChemMedChem, 2014, v. 9, n. 3, p. 602, doi. 10.1002/cmdc.201300270
- By:
- Publication type:
- Article
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00483-1
- By:
- Publication type:
- Article